Metformin improves cognitive impairment in patients with schizophrenia: associated with enhanced functional connectivity of dorsolateral prefrontal cortex
10.1038/s41398-023-02616-x · doi-reference
Beneficial effects of metformin treatment on memory impairment
10.1007/s11033-024-09445-1 · doi-reference
The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression
10.3389/fpsyt.2023.1215807 · doi-reference
Metformin use is associated with a reduced risk of cognitive impairment in adults with diabetes mellitus: a systematic review and meta-analysis
10.3389/fnins.2022.984559 · doi-reference
Long-term metformin usage and cognitive function among older adults with diabetes
10.3233/jad-131901 · doi-reference
Association of metformin use with Alzheimer’s disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study
10.1038/s41598-021-03406-5 · doi-reference
Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS study
10.1186/s12933-023-01817-4 · doi-reference
Individual and combined associations of glucose metabolic components with cognitive function modified by obesity
10.3389/fendo.2021.769120 · doi-reference
Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records
10.1136/bmjdrc-2023-003548 · doi-reference
Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model
10.1007/s13238-021-00858-3 · doi-reference
Metformin normalizes mitochondrial function to delay astrocyte senescence in a mouse model of Parkinson’s disease through Mfn2-cGAS signaling
10.1186/s12974-024-03072-0 · doi-reference
Metformin-induced changes in the gut microbiome and plasma metabolome are associated with cognition in men
10.1016/j.metabol.2024.155941 · doi-reference
Metformin protects from rotenone-induced nigrostriatal neuronal death in adult mice by activating AMPK-FOXO3 signaling and mitigation of angiogenesis
10.3389/fnmol.2020.00084 · doi-reference
Medications and cognitive decline in Alzheimer’s disease: cohort cluster analysis of 15,428 patients
10.1177/13872877241307870 · doi-reference
Unravelling shared pathways linking metabolic syndrome, mild cognitive impairment, dementia, and sarcopenia
10.3390/metabo15030159 · doi-reference
Metformin mitigates trimethyltin-induced cognition impairment and hippocampal neurodegeneration
10.1007/s10571-024-01502-4 · doi-reference
Beneficial effects of metformin treatment in hyperglycaemic patients affected by ischaemia with no obstructive coronary artery
10.1093/cvr/cvae269 · doi-reference
The mechanism and treatment of cognitive dysfunction in diabetes: a review
10.1055/a-2480-7826 · doi-reference
Peripheral inflammation and insulin resistance: their impact on blood-brain barrier integrity and glia activation in Alzheimer’s disease
10.3390/ijms26094209 · doi-reference
Neuro-protective role of metformin in patients with acute stroke and type 2 diabetes mellitus via AMPK/mammalian target of rapamycin (mTOR) signaling pathway and oxidative stress
10.12659/msm.911250 · doi-reference
Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus
10.1136/bmjopen-2018-024954 · doi-reference
Neural ageing and synaptic plasticity: prioritizing brain health in healthy longevity
10.3389/fnagi.2024.1428244 · doi-reference
Underlying mechanisms of brain aging and neurodegenerative diseases as potential targets for preventive or therapeutic strategies using phytochemicals
10.3390/nu15153456 · doi-reference
The association between metformin use and risk of developing severe dementia among AD patients with type 2 diabetes
10.3390/biomedicines11112935 · doi-reference
Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: Pooled analysis from 5 cohorts
10.1371/journal.pone.0212293 · doi-reference
Long-term use of metformin is associated with reduced risk of cognitive impairment with alleviation of cerebral small vessel disease burden in patients with type 2 diabetes
10.3389/fnagi.2021.773797 · doi-reference
Metformin use and cognitive function in older adults with type 2 diabetes following a Mediterranean diet intervention
10.3389/fnut.2021.742586 · doi-reference
AMPK--sensing energy while talking to other signaling pathways
10.1016/j.cmet.2014.09.013 · doi-reference
Prediabetes increases the risk of frailty in prefrail older adults with hypertension: beneficial effects of metformin
10.1161/hypertensionaha.124.23087 · doi-reference
Cognitive impairment in frail hypertensive elderly patients: role of hyperglycemia
10.3390/cells10082115 · doi-reference
Taking metformin and cognitive function change in older patients with diabetes
10.1111/ggi.13692 · doi-reference
The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease
10.1016/j.diabres.2016.12.010 · doi-reference
Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment
10.1016/j.archger.2019.06.001 · doi-reference
Bias in meta-analysis detected by a simple, graphical test
10.1136/bmj.315.7109.629 · doi-reference
Operating characteristics of a rank correlation test for publication bias
10.2307/2533446 · doi-reference
Meta-analysis in clinical trials
10.1016/0197-2456(86)90046-2 · doi-reference
Psychological concerns associated with empathy in paid and unpaid caregivers of older people: a systematic review
10.1080/07317115.2022.2090879 · doi-reference
Factors associated with low health literacy in unpaid caregivers of older people: a systematic review
10.1093/heapro/daae118 · doi-reference
